drugset / Trial / NCT00214877

Methylene Blue for Cognitive Dysfunction in Bipolar Disorder

NCT00214877

RandomizedCrossoverDouble-blindTreatment

Summary

While many bipolar patients treated with mood stabilizing medications experience improvement in their symptoms, some continue to have ongoing difficulties with concentration and memory. The purpose of this study is to look at whether these symptoms can be improved by adding the compound methylene blue to the treatment plan of patients who are already taking lamotrigine. Methylene blue is an available 'over the counter medication' in Canada. It has been studied in the long-term treatment of mood symptoms in bipolar disorder. Several clinical studies done in bipolar disorder report that methylene blue has had positive effects on both cognition and mood. It is important to do further research in this area as we know that, for patients who continue to have ongoing cognitive difficulties, there is no recognized standard of care for bipolar patients who experience these type of deficits.

Timeline

Start
2003-11
Primary completion
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylene Blue Diagnostic / imaging agent 16 mg
Subject Methylene Blue Diagnostic / imaging agent 200 mg

Indications